D. Boral Capital Reaffirms "Buy" Rating for ImmunityBio (NASDAQ:IBRX)

Key Points

• D. Boral Capital reiterated a "Buy" on ImmunityBio with a $23 price target (implying ~203% upside); across analysts the consensus is a "Moderate Buy" with an average target of $14.40.
• The stock faces material legal risk after an FDA warning about allegedly misleading ANKTIVA claims, triggering multiple securities class actions and a steep share-price decline.
• Insiders sold a total of 275,000 shares last quarter despite owning ~69.5% of the company, while ImmunityBio plans to present new ANKTIVA data at the American Urological Association meeting — a near-term clinical catalyst.

ImmunityBio (NASDAQ:IBRX - Get Free Report)'s stock had its "buy" rating reiterated by analysts at D. Boral Capital in a research report issued on Tuesday,Benzinga reports. They currently have a $23.00 price objective on the stock. D. Boral Capital's target price would suggest a potential upside of 203.43% from the company's previous close.

IBRX has been the topic of a number of other reports. The Goldman Sachs Group restated a "buy" rating on shares of ImmunityBio in a report on Monday, February 23rd. Weiss Ratings restated a "sell (d-)" rating on shares of ImmunityBio in a report on Tuesday, April 14th. Piper Sandler restated an "overweight" rating and issued a $12.00 price target (up from $7.00) on shares of ImmunityBio in a report on Wednesday, March 4th. HC Wainwright raised their price target on shares of ImmunityBio from $10.00 to $15.00 and gave the company a "buy" rating in a report on Monday, February 23rd. Finally, BTIG Research started coverage on shares of ImmunityBio in a report on Thursday, March 12th. They issued a "buy" rating and a $13.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, ImmunityBio presently has an average rating of "Moderate Buy" and a consensus target price of $14.40.

ImmunityBio Price Performance

NASDAQ IBRX traded up $0.15 during trading on Tuesday, reaching $7.58. 9,039,931 shares of the company's stock traded hands, compared to its average volume of 31,859,242. The firm has a market cap of $7.79 billion, a price-to-earnings ratio of -19.95 and a beta of 0.02. The company's 50 day simple moving average is $8.13 and its two-hundred day simple moving average is $5.06. ImmunityBio has a 12-month low of $1.83 and a 12-month high of $12.43.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last posted its earnings results on Monday, February 23rd. The company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02. The business had revenue of $38.29 million for the quarter. Research analysts expect that ImmunityBio will post -0.31 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Barry J. Simon sold 75,000 shares of ImmunityBio stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $12.01, for a total value of $900,750.00. Following the completion of the sale, the director directly owned 2,850,821 shares in the company, valued at $34,238,360.21. This trade represents a 2.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Christobel Selecky sold 25,000 shares of ImmunityBio stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $10.00, for a total transaction of $250,000.00. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 275,000 shares of company stock valued at $2,934,500 over the last quarter. 69.48% of the stock is owned by company insiders.

Institutional Trading of ImmunityBio

Several institutional investors and hedge funds have recently bought and sold shares of IBRX. Heights Capital Management Inc. acquired a new stake in ImmunityBio during the 3rd quarter valued at approximately $16,152,000. Vanguard Group Inc. lifted its stake in ImmunityBio by 26.8% during the 3rd quarter. Vanguard Group Inc. now owns 27,655,205 shares of the company's stock valued at $68,032,000 after acquiring an additional 5,837,898 shares during the period. State Street Corp lifted its stake in ImmunityBio by 45.4% during the 4th quarter. State Street Corp now owns 16,455,703 shares of the company's stock valued at $32,582,000 after acquiring an additional 5,139,890 shares during the period. Goldman Sachs Group Inc. lifted its stake in ImmunityBio by 439.4% during the 4th quarter. Goldman Sachs Group Inc. now owns 6,152,684 shares of the company's stock valued at $12,182,000 after acquiring an additional 5,012,001 shares during the period. Finally, Woodline Partners LP lifted its stake in ImmunityBio by 53.7% during the 3rd quarter. Woodline Partners LP now owns 5,297,725 shares of the company's stock valued at $13,032,000 after acquiring an additional 1,851,854 shares during the period. 8.58% of the stock is currently owned by institutional investors and hedge funds.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: ImmunityBio will present new comparative data on ANKTIVA plus BCG (and an update on its BCG‑naïve registrational trial) at the American Urological Association meeting — a near‑term clinical/data catalyst that investors may hope supports commercial prospects. ImmunityBio to Present New Comparative Data at AUA
• Neutral Sentiment: Multiple investor‑rights firms (Rosen, Faruqi, Schall, Bernstein, The Gross Law Firm, etc.) are notifying shareholders about the May 26, 2026 lead‑plaintiff deadline and soliciting clients — this is administrative but reinforces that litigation activity is widespread. Shareholders Have Opportunity to Lead Securities Fraud Lawsuit
• Negative Sentiment: Hagens Berman and other firms say the company was sued after the FDA sent a warning letter about allegedly misleading claims by the company’s executive chairman regarding ANKTIVA efficacy; Hagens Berman notes a ~21% share plunge and a multi‑billion dollar market‑cap hit. The FDA concern is the root cause of the legal exposure. IBRX Sued After FDA Flags Misleading Cancer Claims
• Negative Sentiment: Multiple separate securities class actions and investor alerts have been filed/announced (Bernstein Liebhard, Levi & Korsinsky, Schall, Rosen, Faruqi, Gross, etc.), alleging violations tied to statements about ANKTIVA and seeking lead plaintiffs — this increases potential litigation costs, management distraction, and downside risk to the share price. Investors Have Opportunity to Lead Securities Fraud Lawsuit

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.